Biotechnology developer BiVictriX Therapeutics announced the appointment of Dr Adrian Howd as its chief financial officer (CFO) and chief business officer (CBO) on Tuesday.
The AIM-traded firm said Dr Howd would take over from outgoing finance chief Alex Hughes, whose departure would take effect on 13 October.
Bringing in more than two decades of expertise in strategic financial management and commercial operations within the biopharmaceutical domain, BiVictriX said Dr Howd was well-poised to steer its financial and business dimensions.
In his previous stints with global financial entities such as Berenberg Bank, ABN Amro and Nomura, Dr Howd accumulated substantial experience in the equity capital markets, both in the UK and internationally.
His tenure as chief investment officer and chief executive officer at investment firm Malin saw him elevate the company to its debut on the Irish Stock Exchange and placed him as a pivotal player in one of the most significant European life science initial public offerings to date.
“We are delighted to welcome Adrian as chief financial officer and chief business officer,” said chief executive officer Tiffany Thorn.
“His substantial financial acumen, combined with his strong track record of strategic and operational success with UK oncology businesses, will be invaluable as we look to secure partnership deals and accelerate BiVictriX towards our next phase of development.
“On behalf of the entire team, I would like to express my thanks to Alex for his contributions to the company and wish him all the best in his future endeavours.”
Reporting by Josh White for Sharecast.com.
